Home › Companies › ARS Pharmaceuticals, Inc. › 2024-2025
At ARS Pharmaceuticals, Inc.'s shareholder meeting held June 25, 2025, in the 2024-2025 proxy season, 53 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 746 separate fund positions. On the most widely held item on that ballot — To elect the four nominees for Class II director named in the proxy statement to serve for… — ARS Pharmaceuticals, Inc.'s filing reports the nominee as elected, with 83% support of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ARS Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 26, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ARS Pharmaceuticals, Inc.’s Form 8-K, filed June 26, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 25, 2025: 5 items on ARS Pharmaceuticals, Inc.’s Form 8-K, filed June 26, 2025: 4 elected · 1 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore ARS Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are ARS Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 26, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Richard Lowenthal, M.S., MSEL | 64,911,098 | -- | -- | 3,015,787 | 9,563,130 | 96% | Elected | — |
| Elect Director: Peter Kolchinsky, Ph.D. | 55,848,125 | -- | -- | 12,078,760 | 9,563,130 | 82% | Elected | — |
| Elect Director: Brenton L. Saunders | 56,161,307 | -- | -- | 11,765,578 | 9,563,130 | 83% | Elected | — |
| Elect Director: Peter A. Thompson, M.D. | 61,822,896 | -- | -- | 6,103,989 | 9,563,130 | 91% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 77,258,380 | 162,857 | 68,778 | -- | 0 | 99.7% | Approved | — |
Source: ARS Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 26, 2025 — read the filing on EDGAR.
Each item below shows how the 53 asset managers that disclosed a ARS Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Brenton L. Saunders
ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Brenton L. Saunders”): 56,161,307 for, 11,765,578 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the four persons listed below as Class II directors, each to serve until the Company's 2028 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resignati…”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 1,888,321 for, 6,381,826 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AllianceBernstein | 0 | 0 | 0 | 1,332,922 | Withhold |
| Aberdeen | 0 | 0 | 0 | 1,190,480 | Withhold |
| Vanguard | 0 | 0 | 0 | 838,524 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 795,845 | Withhold |
| FRANKLIN STRATEGIC SERIES | 654,375 | 0 | 0 | 0 | For |
| Royce | 539,187 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 509,883 | Withhold |
| BlackRock | 358,865 | 0 | 0 | 16,232 | For |
| Equitable | 8,925 | 0 | 0 | 350,069 | Withhold |
| Principal | 0 | 0 | 0 | 266,314 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 168,770 | Withhold |
| Neuberger Berman | 0 | 0 | 0 | 160,710 | Withhold |
| First Trust | 0 | 0 | 0 | 144,075 | Withhold |
| OPTIMUM FUND TRUST | 142,668 | 0 | 0 | 0 | For |
| Fidelity | 32,276 | 0 | 0 | 99,656 | Mixed |
| Advisors' Inner Circle Fund III | 39,285 | 0 | 0 | 80,361 | Mixed |
| Columbia Threadneedle | 79,461 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 65,389 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 56,292 | Withhold |
| State Street | 132 | 0 | 0 | 46,631 | Withhold |
| SEI | 0 | 0 | 0 | 42,526 | Withhold |
| Northern Trust | 0 | 0 | 0 | 32,954 | Withhold |
| Brighthouse | 0 | 0 | 0 | 28,186 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 27,363 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 25,779 | Withhold |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Peter A. Thompson
ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Peter A. Thompson, M.D.”): 61,822,896 for, 6,103,989 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the four persons listed below as Class II directors, each to serve until the Company's 2028 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resignati…”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 5,554,298 for, 2,715,849 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AllianceBernstein | 1,332,922 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 1,190,480 | Withhold |
| Vanguard | 838,524 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 795,845 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 654,375 | 0 | 0 | 0 | For |
| Royce | 539,187 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 509,883 | Withhold |
| BlackRock | 0 | 0 | 0 | 375,097 | Withhold |
| Equitable | 350,069 | 0 | 0 | 8,925 | For |
| Principal | 266,314 | 0 | 0 | 0 | For |
| Charles Schwab | 168,770 | 0 | 0 | 0 | For |
| Neuberger Berman | 160,710 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 144,075 | Withhold |
| OPTIMUM FUND TRUST | 142,668 | 0 | 0 | 0 | For |
| Fidelity | 14,263 | 0 | 0 | 117,669 | Mixed |
| Advisors' Inner Circle Fund III | 119,646 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 79,461 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 65,389 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 56,292 | Withhold |
| State Street | 132 | 0 | 0 | 46,631 | Withhold |
| SEI | 42,526 | 0 | 0 | 0 | For |
| Northern Trust | 32,954 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 28,186 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 27,363 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 25,779 | Withhold |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Peter Kolchinsky
ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Peter Kolchinsky, Ph.D.”): 55,848,125 for, 12,078,760 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the four persons listed below as Class II directors, each to serve until the Company's 2028 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resignati…”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 2,502,042 for, 5,768,105 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AllianceBernstein | 0 | 0 | 0 | 1,332,922 | Withhold |
| Aberdeen | 0 | 0 | 0 | 1,190,480 | Withhold |
| Vanguard | 838,524 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 795,845 | Withhold |
| FRANKLIN STRATEGIC SERIES | 654,375 | 0 | 0 | 0 | For |
| Royce | 539,187 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 509,883 | Withhold |
| BlackRock | 0 | 0 | 0 | 375,097 | Withhold |
| Equitable | 0 | 0 | 0 | 358,994 | Withhold |
| Principal | 0 | 0 | 0 | 266,314 | Withhold |
| Charles Schwab | 168,770 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 0 | 0 | 160,710 | Withhold |
| First Trust | 0 | 0 | 0 | 144,075 | Withhold |
| OPTIMUM FUND TRUST | 142,668 | 0 | 0 | 0 | For |
| Fidelity | 113,919 | 0 | 0 | 18,013 | Mixed |
| Advisors' Inner Circle Fund III | 39,285 | 0 | 0 | 80,361 | Mixed |
| Columbia Threadneedle | 0 | 0 | 0 | 79,461 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 65,389 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 56,292 | Withhold |
| State Street | 132 | 0 | 0 | 46,631 | Withhold |
| SEI | 0 | 0 | 0 | 42,526 | Withhold |
| Northern Trust | 0 | 0 | 0 | 32,954 | Withhold |
| Brighthouse | 0 | 0 | 0 | 28,186 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 27,363 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 25,779 | Withhold |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Richard Lowenthal
ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Richard Lowenthal, M.S., MSEL”): 64,911,098 for, 3,015,787 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the four persons listed below as Class II directors, each to serve until the Company's 2028 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resignati…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 7,261,396 for, 1,008,751 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AllianceBernstein | 1,332,922 | 0 | 0 | 0 | For |
| Aberdeen | 1,190,480 | 0 | 0 | 0 | For |
| Vanguard | 838,524 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 795,845 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 654,375 | 0 | 0 | 0 | For |
| Royce | 539,187 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 509,883 | Withhold |
| BlackRock | 375,097 | 0 | 0 | 0 | For |
| Equitable | 358,994 | 0 | 0 | 0 | For |
| Principal | 266,314 | 0 | 0 | 0 | For |
| Charles Schwab | 168,770 | 0 | 0 | 0 | For |
| Neuberger Berman | 160,710 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 144,075 | Withhold |
| OPTIMUM FUND TRUST | 142,668 | 0 | 0 | 0 | For |
| Fidelity | 32,276 | 0 | 0 | 99,656 | Mixed |
| Advisors' Inner Circle Fund III | 119,646 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 79,461 | 0 | 0 | 0 | For |
| Lincoln Financial | 36,600 | 0 | 0 | 28,789 | Mixed |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 56,292 | Withhold |
| State Street | 46,705 | 0 | 0 | 58 | For |
| SEI | 42,526 | 0 | 0 | 0 | For |
| Northern Trust | 32,954 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 28,186 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 27,363 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 25,779 | Withhold |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.
ARS Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 77,258,380 for, 162,857 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 8,241,962 for, 28,185 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AllianceBernstein | 1,332,922 | 0 | 0 | 0 | For |
| Aberdeen | 1,190,480 | 0 | 0 | 0 | For |
| Vanguard | 838,524 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 795,845 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 654,375 | 0 | 0 | 0 | For |
| Royce | 539,187 | 0 | 0 | 0 | For |
| Allspring | 509,883 | 0 | 0 | 0 | For |
| BlackRock | 375,097 | 0 | 0 | 0 | For |
| Equitable | 358,994 | 0 | 0 | 0 | For |
| Principal | 266,314 | 0 | 0 | 0 | For |
| Charles Schwab | 168,770 | 0 | 0 | 0 | For |
| Neuberger Berman | 160,710 | 0 | 0 | 0 | For |
| First Trust | 144,075 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 142,668 | 0 | 0 | 0 | For |
| Fidelity | 131,932 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 119,646 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 79,461 | 0 | 0 | 0 | For |
| Lincoln Financial | 65,389 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 56,292 | 0 | 0 | 0 | For |
| State Street | 46,763 | 0 | 0 | 0 | For |
| SEI | 42,526 | 0 | 0 | 0 | For |
| Northern Trust | 32,954 | 0 | 0 | 0 | For |
| Brighthouse | 1 | 0 | 28,185 | 0 | Abstain |
| Direxion Shares ETF Trust | 27,363 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 25,779 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 98,129,804 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | AllianceBernstein | 1.36% |
| 2 | Aberdeen | 1.21% |
| 3 | Vanguard | 0.85% |
| 4 | AB DISCOVERY GROWTH FUND, INC. | 0.81% |
| 5 | FRANKLIN STRATEGIC SERIES | 0.67% |
| 6 | Royce | 0.55% |
| 7 | Allspring | 0.52% |
| 8 | BlackRock | 0.38% |
| 9 | Equitable | 0.37% |
| 10 | Principal | 0.27% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BRANDYWINE OAK PRIVATE WEALTH LLC | <0.01% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 11.15% | 13D |
| Peter Kolchinsky, Ph.D. | 11.11% | DEF14A |
| Entities affiliated with RA Capital | 11.07% | DEF14A |
| Entities affiliated with Deerfield Management Company, L.P. | 10.72% | DEF14A |
| Entities affiliated with OrbiMed Advisors LLC | 8.56% | DEF14A |
| Richard Lowenthal, M.S., MSEL | 8.25% | DEF14A |
| Rubric Capital Management LP | 8.15% | 13G |
| Deerfield Management Company, L.P. | 7.76% | 13D |
| Pratik Shah, Ph.D. | 5.32% | DEF14A |
| Sarina Tanimoto, M.D., M.B.A. | 5.00% | DEF14A |
Percentages above are of 98,129,804 shares outstanding, as reported by ARS Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARS Pharmaceuticals, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ARS Pharmaceuticals, Inc. proxy season coverage: 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “ARS Pharmaceuticals (SPRY) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ars-pharmaceuticals-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.